Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Gross Profit: 2024-2025

Historic Gross Profit for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to $12.8 million.

  • Monte Rosa Therapeutics' Gross Profit rose 38.54% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $181.5 million, marking a year-over-year change of. This contributed to the annual value of $75.6 million for FY2024, which is N/A change from last year.
  • Monte Rosa Therapeutics' Gross Profit amounted to $12.8 million in Q3 2025, which was down 44.95% from $23.2 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Gross Profit ranged from a high of $84.9 million in Q1 2025 and a low of $1.1 million during Q1 2024.
  • For the 2-year period, Monte Rosa Therapeutics' Gross Profit averaged around $28.1 million, with its median value being $12.8 million (2025).
  • Data for Monte Rosa Therapeutics' Gross Profit shows a peak YoY surged of 7,882.05% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Monte Rosa Therapeutics' Gross Profit stood at $60.6 million in 2024, then surged by 38.54% to $12.8 million in 2025.
  • Its Gross Profit was $12.8 million in Q3 2025, compared to $23.2 million in Q2 2025 and $84.9 million in Q1 2025.